| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland 21201
Address all correspondence and requests for reprints to: Angela Brodie, Ph.D., University of Maryland School of Medicine, Pharmacology & Experimental Therapeutics, 655 West Baltimore Street, Baltimore, Maryland 21201. E-mail: abrodie{at}umaryland.edu
The C17,20-lyase and 5
-reductase are key enzymes in the
biosynthesis of androgens. The effects of novel steroidal compounds
were evaluated as inhibitors against both human
C17,20-lyase and 5
-reductase in
vitro. The concentrations of testosterone (T) and
dihydrotestosterone (DHT) in the prostate, testis and serum and changes
in the tissue weights were also determined in rats treated with the
novel inhibitors. L-12 and L-26 showed potent inhibition of human
testicular C17,20-lyase with IC50 values of 50
and 25 nM, respectively. L-12, L-38, and I-47 showed
moderate inhibition of human testicular C17,20-lyase with
IC50 values of 75, 108, and 70 nM, respectively
similar to ketoconazole (78 nM). Interestingly, L-6, L-26,
and L-38 also showed some inhibitory activity against 5
-reductase
with IC50 values of 75, 125, and 377 nM,
respectively. Finasteride, an inhibitor of 5
-reductase
had an IC50 value of 33 nM. However,
ketoconazole did not inhibit 5
-reductase nor did
finasteride inhibit C17,20-lyase. Treatment of
normal male rats with several of these novel inhibitors (50
mg/kg·day, sc, for 14 consecutive days) caused about 4591%
decrease in serum, testicular and prostatic T concentration. Similarly,
serum and prostatic DHT concentration were significantly decreased in
rats treated with these novel compounds by 5090% compared with
controls. Surgical castration caused almost complete elimination of
circulating T and DHT concentration in rat tissues. L-6 and L-12 were
the most effective and reduced the wet weight of the prostate by 50%.
Although future improvements in their bioavailability are necessary,
these novel steroidal compounds show promise as potential agents for
reducing T and DHT levels in patients with androgen dependent diseases.
This article has been cited by other articles:
![]() |
W. A. Fritz, M. S. Cotroneo, J. Wang, I.-E. Eltoum, and C. A. Lamartiniere Dietary Diethylstilbestrol but Not Genistein Adversely Affects Rat Testicular Development J. Nutr., July 1, 2003; 133(7): 2287 - 2293. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Long, D. N. Grigoryev, I. P. Nnane, Y. Liu, Y.-Z. Ling, and A. M. Brodie Antiandrogenic Effects of Novel Androgen Synthesis Inhibitors on Hormone-dependent Prostate Cancer Cancer Res., December 1, 2000; 60(23): 6630 - 6640. [Abstract] [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |